Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients

被引:0
|
作者
Wang, Zhenhua [1 ,2 ]
Wu, Shuming [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Div Gastroenterol & Hepatol,Shanghai Inst Digest, Shanghai 200001, Peoples R China
[2] Shanghai Jiao Tong Univ, Key Lab Gastroenterol & Hepatol, Minist Hlth, Shanghai 200001, Peoples R China
关键词
doxycycline; Helicobacter pylori; quadruple therapy; rescue therapy; TRIPLE THERAPY; GASTRIC-CANCER; INFECTION; RESISTANCE; CLARITHROMYCIN; METRONIDAZOLE; 2ND-LINE; IMPACT; LEVOFLOXACIN; LANSOPRAZOLE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction This study aimed to compare the efficacy and safety of quadruple therapy containing doxycycline and routine quadruple therapy for Helicobacter (H.) pylori rescue eradication in patients who had failed the one-week triple therapy. Methods Patients who failed the first-line eradication therapy were allocated into two groups. Group A patients (n = 43) were administered esomeprazole 20 mg, bismuth potassium citrate 220 mg, amoxicillin 1 g and doxycycline 100 mg, all bid for ten days, while Group B patients (n = 42) were administered esomeprazole 20 mg bid, bismuth potassium citrate 220 mg bid, metronidazole 400 mg bid and tetracycline 750 mg q.6h, for ten days. The results of H. pylori eradication were assessed with 13C urea breath test four weeks after the therapy, and the side effects were recorded. Results A total of 85 patients (average age 46.9 years) were enrolled in the study. Successful eradication rate for H. pylori was 72.5% in Group A and 64.1% in Group B, with no significant difference between the two groups. 11.6% (5/43) of patients from group A and 31.0% (13/42) from group B reported at least one adverse event. The adverse events of all 18 patients disappeared after the therapy ceased. Conclusion Quadruple therapy containing doxycycline is as effective as routine quadruple therapy for H. pylori rescue eradication. The regimen is well tolerated by most patients and causes fewer adverse events than routine quadruple therapy. Hence, it may be recommended as a suitable alternative H. pylori rescue regimen in China.
引用
收藏
页码:273 / 276
页数:4
相关论文
共 50 条
  • [41] Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial
    So Jeong Kim
    Jun-Won Chung
    Hyun Sun Woo
    Su Young Kim
    Jung Ho Kim
    Yoon Jae Kim
    Kyoung Oh Kim
    Kwang An Kwon
    Dong Kyun Park
    World Journal of Gastroenterology, 2019, 25 (46) : 6790 - 6798
  • [42] ERADICATION RATE AND SAFETY OF REDUCED-TETRACYCLINE VS STANDARD-TETRACYCLINE, FURAZOLIDONE-CONTAINING QUADRUPLE REGIMEN FOR HELICOBACTER PYLORI INFECTION: A SINGLE CENTER RETROSPECTIVE STUDY IN CHINA
    Sun, Yingchao
    Zhu, Mengjia
    Yue, Lei
    Zhao, Yiru
    Hu, Weiling
    GASTROENTEROLOGY, 2023, 164 (06) : S379 - S379
  • [43] Eradication rate of Helicobacter pylori infection in Chinese duodenal ulcer patients treated with Vonoprazan 20 mg versus Lansoprazole 30 mg with bismuth containing quadruple therapy
    Wang, J.
    Hou, X.
    Meng, F.
    Sha, W.
    Gu, L.
    Kudou, K.
    Dong, L.
    Xie, L.
    Zhang, S.
    HELICOBACTER, 2020, 25 : 7 - 8
  • [44] Efficacy of a New Therapeutic Regimen Versus Two Routinely Prescribed Treatments for Eradication of Helicobacter Pylori: A Randomized, Double-Blind Study of Doxycycline, Co-Amoxiclav, and Omeprazole in Iranian Patients
    Seyed Alireza Taghavi
    Ali Jafari
    Ahad Eshraghian
    Digestive Diseases and Sciences, 2009, 54
  • [45] Efficacy of a New Therapeutic Regimen Versus Two Routinely Prescribed Treatments for Eradication of Helicobacter Pylori: A Randomized, Double-Blind Study of Doxycycline, Co-Amoxiclav, and Omeprazole in Iranian Patients
    Taghavi, Seyed Alireza
    Jafari, Ali
    Eshraghian, Ahad
    DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (03) : 599 - 603
  • [46] Efficacies of different proton pump inhibitor-based 14-day bismuth–furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial
    Luyi Chen
    Jiamin He
    Lan Wang
    Qiwei Ge
    Hua Chu
    Yujia Chen
    Xiaoli Chen
    Yanqin Long
    Yanyong Deng
    Huiqin He
    Aiqing Li
    Shujie Chen
    Clinical and Experimental Medicine, 2018, 18 : 569 - 576
  • [47] Bismuth-based quadruple therapy versus standard triple therapy for the eradication of Helicobacter pylori in Belgium: a multicentre, non-blinded randomized, prospective study
    Francois, S.
    Mana, F.
    Ntounda, R.
    Lamy, V.
    Cadranel, S.
    Bontems, P.
    Deyi, V. Miendje
    Macken, E.
    Kindt, S.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2024, 87 (02) : 235 - 240
  • [48] Open-label study of a regimen consisting of 1 week of lansoprazole, clarithromycin, and amoxicillin followed by 3 weeks of lansoprazole in healing peptic ulcer and eradicating Helicobacter pylori
    Archimandritis, A
    Avgerinos, A
    Nakos, A
    Viazis, N
    Skandalis, N
    Tzivras, M
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2000, 61 (07): : 406 - 413
  • [49] 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial
    Amiot, Aurelien
    Hacoon, Jeremy
    Heluwaert, Frederic
    Mion, Francois
    Lamarque, Dominique
    Moussata, Driffa
    Mimouni, Maroua
    Delchier, Jean-Charles
    Durand-Zaleski, Isabelle
    Audureau, Etienne
    Bastuji-Garin, Sylvie
    HELICOBACTER, 2024, 29 (02)
  • [50] IMPACT OF HELICOBACTER PYLORI ERADICATION ON HEPATIC STEATOSIS, NAFLD FIBROSIS SCORE AND HSENSI IN NONALCOHOLIC STEATOHEPATITIS PATIENTS: AN MRI-BASED PILOT OPEN-LABEL STUDY
    Polyzos, S. A.
    Moschos, J.
    Chatzopoulos, D.
    Nikolopoulos, P.
    Stogianni, A.
    Romiopoulos, I.
    Katsinelos, P.
    Zavos, C.
    Kountouras, J.
    HELICOBACTER, 2015, 20 : 122 - 122